SVN-015 advances through NIDA-funded studies as Solvonis develops a non-hallucinogenic ibogaine analogue for opioid use disorder and withdrawal

SVN-015 is advancing in NIDA-funded studies as Solvonis develops a non-hallucinogenic ibogaine analogue aimed at opioid use disorder, withdrawal, and relapse prevention. The program centers on preserving ibogaine's anti-addictive potential while removing hallucinogenic and cardiotoxic liabilities that have limited broader clinical use. Preclinical work highlights evaluation in animal models relevant to dependence, withdrawal, and drug-seeking behavior, alongside safety-focused development. NIDA support signals external interest in compounds that may address addiction without the perceptual intensity or medical risk associated with ibogaine itself. Non-hallucinogenic ibogaine analogues sit at the intersection of addiction medicine and psychedelic-inspired drug development. If efficacy and safety hold up, SVN-015 could widen the therapeutic playbook for substance use treatment by translating lessons from ibogaine into a more scalable pharmaceutical candidate.